FIGO

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, March 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

Retrieved on: 
Monday, March 11, 2024
HER2, Cervical cancer, Congress, ECOG, Immunotherapy, Progression-free survival, DCR, Patient, Research, IIB, Șaeș, Safety, Dor, Carcinoma, ESGO, Adenocarcinoma, PFS, FIGO, ADC, Independent Review Committee, Pharmaceutical industry

The cervical cancer cohort includes patients with recurrent or metastatic cervical cancer who have progressed on at least 1L anti-tumor therapy and have HER2 IHC ≥1+.

Key Points: 
  • The cervical cancer cohort includes patients with recurrent or metastatic cervical cancer who have progressed on at least 1L anti-tumor therapy and have HER2 IHC ≥1+.
  • As of October 31, 2023, 25 patients with cervical cancer were enrolled with a median age of 56 years (range: 35-66).
  • In conclusion, RC48 demonstrates a manageable safety profile and positive efficacy in HER2-expressing r/m cervical cancer patients, suggesting it to be a promising new treatment for HER2-expressed cervical cancer.
  • I am delighted to share an oral presentation on the evaluation of our proprietary ADC Disitamab Vedotin at ESGO 2024.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Platinum, Artery, INN, HER2, Histology, Hypertension, Cancer, Neoplasm, Anatomy, Paclitaxel, IIA, Diarrhea, Breast, Fatigue, Breast cancer, ATC, Embolism, Bleeding, VEGF, Weakness, Abdomen, Capecitabine, Pregnancy, Human, Safety, Gynaecology, NSCLC, Patient, Medical Subject Headings, Peritoneum, EGFR, Carboplatin, International, FIGO, Nutrient, Language, Blood, Cisplatin, Rectum, Oxygen, Anthracycline, Select, Ovary, Lung cancer, Allergy, Recurrence, European Medicines Agency, Growth, Doxorubicin, Taxane

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Retrieved on: 
Monday, October 2, 2023
Vaccine, DNA, Biotechnology, University, FIGO, Nucleic acid thermodynamics, PDSB, Neoplasm, ASTRO, Infection, HPV16, Cancer, SOC, Monroe Dunaway Anderson, Radiation therapy, Doctor of Philosophy, MD Anderson Cancer Center, CD8, Cervical cancer, MD, Patient, Lymph, Blood, Annual general meeting, American Society for Radiation Oncology, HPV, Chemoradiotherapy, Gynaecology, Oncology, CRT, Kinetics, Society, Human papillomavirus infection, Disease, Birth control, Medical imaging, Obstetrics

HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.

Key Points: 
  • HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.
  • HPV type 16 (HPV16) is the most prominent subtype associated with cervical cancer.
  • Longitudinal plasma samples were collected from each patient at baseline, during weeks 1, 3, and 5, and at 3-4 months after CRT.
  • “I look forward to the continued evaluation of PDS0101 in combination with standard-of-care chemoradiotherapy.”

ACCESS Consensus Group: Experts Warn of an Increase in Cervical Cancer if Under-screened Women Are Not Prioritised

Retrieved on: 
Thursday, July 20, 2023
Consensus, Partnership, International, FIGO, Vaccination, White paper, Tide, Cervical cancer, Woman, ACCESS, Risk, Head, Elimination, Disability-adjusted life year, HPV, WHO, Birth control

Philippe Descamps, Vice President of FIGO and co-chair of the ACCESS International Consensus Group on Cervical Cancer.

Key Points: 
  • Philippe Descamps, Vice President of FIGO and co-chair of the ACCESS International Consensus Group on Cervical Cancer.
  • Samantha Dixon, Chief Executive Officer of Jo's Cervical Cancer Trust, and co-chair of the ACCESS International Consensus Group on Cervical Cancer.
  • The Consensus Group proposes a series of evidence-based recommendations and best practice examples to improve outcomes by increasing cervical cancer screening participation among under-screened women.
  • The Consensus Group urges decision-makers to implement the recommendations outlined in the White Paper, ensuring women have optimal access to cervical cancer screening, which is a vital cancer prevention tool.

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

Retrieved on: 
Monday, November 14, 2022
Trial of the century, Communication, Survival, Neck, Lymph, National Cancer Institute, Type 1, CT scan, Cancer, Mayo Clinic, Disease, Radiation, PDS, Toxicity, Immunotherapy, Treatment, Vaccine, Cervical cancer, Blood, Partnership, PET, University, Neoplasm, Research, Nature, Society, MD Anderson Cancer Center, Biotechnology, COVID-19, Merck & Co., Vulvar cancer, Warfarin necrosis, NCI, Merck, MRI, Human, CD8, Sharp, Nominal interest rate, Clinical professor, Therapy, FIGO, CRT, CPI, Gamma ray, III, Risk, Infection, Merck Sharp & Dohme Federal Credit Union, PDSB, Positron emission tomography, CR, Head, SITC, Pharmaceutical industry, Medical imaging, Patient

FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial was presented during a poster session on November 11 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022). These data expand upon results detailed in the abstract submitted to SITC 2022 that was released to the public on November 7.

Key Points: 
  • This includes 78% (7/9) of treated patients with advanced cervical cancer (FIGO stage III or IV).
  • 100% (9/9) of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage >60% at mid-point evaluation by MRI.
  • We look forward to the continued advancement of the IMMUNOCERV Phase 2 clinical trial and the opportunity to report updated data during 2023.
  • A third Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer is being led by The University of Texas MD Anderson Cancer Center.

Worldwide Pet Insurance Industry to 2027 - by Animal Type, Insurance Type, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Professional Services, Insurance, Pets, Consumer, Dog, Cat, Agency, Accidental, Disease, PETS, Trupanion, Animal, Urbanization, Loneliness, Ageing, Insurance, Policy, USD, Research, USAA, Accident, The Sims 4: Cats & Dogs, Maintenance, Growth, FIGO, City, Hilltop Holdings Inc., Direct Line Group, The Oriental Insurance Company, Pet, Direct, Broker, Bancassurance

In the year 2016, the value of the pet insurance market was at USD 3.46 Billion.

Key Points: 
  • In the year 2016, the value of the pet insurance market was at USD 3.46 Billion.
  • As the healthcare costs for pets are going through the roof with innovations and rising demand, pet owners are increasingly adopting pet insurance schemes.
  • This is to have a direct impact on the cat pet insurance too, growing at a CAGR of 13%.
  • Agria Pet Insurance Limited, FIGO PET INSURANCE, LLC (figo), Nationwide, PETFIRST pet insurance, PETHEALTH, PETPLAN PET INSURANCE, PetSure, Trupanion, Crum & Forster Pet Insurance Group, Direct, Line Group, PetSecure Pet Insurance, TRUSTEDPALS, RSA Group, USAA, Oriental Insurance, Anicom, Holdings Inc., Tokio Marine & Nichido Fire Insurance Co.Ltd.

JAB’s Pinnacle Pet Group Expands Through Acquisition of Veterfina’s European Pet Insurance Business

Retrieved on: 
Wednesday, July 6, 2022
Veterinary, Technology, Insurance, Pets, Other Technology, Health Technology, Professional Services, Software, Consumer, Health, Insurance, Acquisition, Knowledge, CEO, Coffee, FIGO, Ownership, Pet insurance, Company, Coty Inc., BNP Paribas, D2C, PPG, JAB, Beauty, NVA, Espresso House, Keurig Dr Pepper, Pret a Manger, JDE, Dog, Cardif, Bally, Panera Bread, Health, Omnichannel, Bagel, Caribou Coffee, News, Group, Veterinarian, Cat, JAB Holding Company, Risk management, Pet

This will include the introduction of FIGO, JABs D2C pet insurance brand and digital platform, in select European markets.

Key Points: 
  • This will include the introduction of FIGO, JABs D2C pet insurance brand and digital platform, in select European markets.
  • We continue to see significant growth opportunities in the European pet insurance and pet healthcare sector, said Joachim Creus, Managing Partner at JAB and Chairman of the JAB pet insurance platform.
  • We are thrilled to welcome Veterfina and its whole team to the Pinnacle Pet Group, said Dirk Beeckman, CEO of JAB pet insurance platform and PPG.
  • Pinnacle Pet Group (PPG or the Group) is a pan-European, fully integrated pet insurance & health services platform indirectly owned by JAB Holding Company.